<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Seth Berkley on Medium]]></title>
        <description><![CDATA[Stories by Seth Berkley on Medium]]></description>
        <link>https://medium.com/@GaviSeth?source=rss-4f701633ecd------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*uykMLaagZvPmEooi.jpeg</url>
            <title>Stories by Seth Berkley on Medium</title>
            <link>https://medium.com/@GaviSeth?source=rss-4f701633ecd------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 20:14:15 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@GaviSeth/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Saving antibiotics so that antibiotics can save lives]]></title>
            <link>https://medium.com/@GaviSeth/saving-antibiotics-so-that-antibiotics-can-save-lives-ffa571462922?source=rss-4f701633ecd------2</link>
            <guid isPermaLink="false">https://medium.com/p/ffa571462922</guid>
            <category><![CDATA[vaccines]]></category>
            <category><![CDATA[antibiotics]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Seth Berkley]]></dc:creator>
            <pubDate>Tue, 20 Sep 2016 15:27:15 GMT</pubDate>
            <atom:updated>2016-09-20T15:27:15.642Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*S_HrxajyUS8XWuT9yefEpA.jpeg" /><figcaption>Getty Images / Cultura Exclusive</figcaption></figure><p>Ever since antibiotics were first developed and heralded as a miracle of modern medicine more than half a century ago, experts have warned of the dangers of their misuse. By exposing bugs to just enough medicine to encourage resistance, the fear was that we would end up encouraging germs to evade the very drugs that were designed to counter their impact.</p><p>The warnings weren’t heeded. In just a few decades, the widespread failure of our best drugs went from being a far-off possibility to a global reality. Currently, 700,000 people die every year because of drug-resistant pathogens, with those living in the poorest parts of the world being hit hardest. But this isn’t just about antibiotics. It also applies to drugs used against big global killers such as HIV and malaria.</p><p>Without immediate action, previously treatable infections and minor surgical procedures will once again become potentially fatal, killing an estimated 10 million people a year by 2050, according to the <a href="http://amr-review.org/">Review on Antimicrobial Resistance</a>. The lives lost could cost the global economy $100 trillion. Add to this the cost of treatment, lost productivity, longer hospitalizations and the knock-on effects on farmers and livestock, and the scale of the problem becomes apparent…</p><p><em>First published by the Wall Street Journal on 15th September 2016. To find out how we solve this problem, please read the rest of this </em><a href="http://www.wsj.com/articles/saving-antibiotics-so-that-antibiotics-can-save-lives-1473969084"><em>article</em></a><em>, jointly written by Jeremy Farrar of the Wellcome Trust.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ffa571462922" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Yellow Fever: Preventing a Return of the Urban Epidemic]]></title>
            <link>https://medium.com/@GaviSeth/yellow-fever-preventing-a-return-of-the-urban-epidemic-db80bf19dae5?source=rss-4f701633ecd------2</link>
            <guid isPermaLink="false">https://medium.com/p/db80bf19dae5</guid>
            <category><![CDATA[epidemiology]]></category>
            <category><![CDATA[global-health]]></category>
            <category><![CDATA[infectious-disease]]></category>
            <category><![CDATA[vaccines]]></category>
            <category><![CDATA[angola]]></category>
            <dc:creator><![CDATA[Seth Berkley]]></dc:creator>
            <pubDate>Thu, 21 Jul 2016 09:44:02 GMT</pubDate>
            <atom:updated>2016-07-21T15:03:22.952Z</atom:updated>
            <content:encoded><![CDATA[<p>In 1793 the US capital of Philadelphia was in a state of crisis. A deadly virus gripped the city forcing the President, George Washington, and other members of his administration to flee, bringing the government to a standstill. By the time the disease had run its course, one tenth of the city’s population had lost their lives. The cause was not smallpox, plague or Spanish flu, but Yellow Fever — a tropical virus which in the 21st century is more often viewed as an exotic disease, and usually confined to Africa and parts of South America. But now that could all change.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*l_Xo-ADIb2w4HpRjqXUSWw.jpeg" /><figcaption>Aedes aegypti. Photo credit: <a href="https://commons.wikimedia.org/wiki/File:Aedes_aegypti.jpg">Muhammad Mahdi Karim</a></figcaption></figure><p>As the largest Yellow Fever outbreak in 30 years continues to spread in and around the capital city of Luanda, Angola, and now to the Democratic Republic of Congo’s (DRC) capital, Kinshasa, there is a growing concern that we could start to see a re-emergence of urban epidemics like the one in Philadelphia. Declining efforts to control Aedes aegypti, the mosquito that usually transmits the disease, have led to its spread, prompting fears that Yellow Fever will return to regions where it was once banished, or even take hold in new parts of the world like Asia. Globalization and recent exports of cases from Angola to DRC, Kenya and China only emphasize the risk. Furthermore, the surge in demand has already placed global vaccine stocks under serious pressure, leaving us potentially even more vulnerable.</p><p>We have faced similar epidemic threats recently with Ebola and Zika, but with Yellow Fever the big difference is that a highly effective and safe vaccine already exists and has done so for more than half a century, requiring just one dose for lifetime protection. This begs the question how we ended up in this situation.</p><blockquote>The fact that we have four manufacturers of a vaccine first produced in the 1930s and are still having to resort to the use of fractional doses — where one fifth of the normal dose will be used per person — because we don’t have an adequate supply, means that something is not working.</blockquote><p>This gets to some of the biggest challenges we face with modern vaccine production.</p><p>For now, despite the scale of the Angola outbreak, vaccine demand is currently mostly still being met. The problem is that of roughly 90 million doses of Yellow Fever vaccine produced globally this year, nearly 13 million have already gone towards dealing with this one situation and now in August, in what is arguably one of the biggest vaccination campaigns ever, we are preparing to vaccinate a further 15.5 million people in Angola and DRC, and all in the space of just one month. That has meant diverting doses away from preventative campaigns, increasing the risk of further outbreaks elsewhere and leaving emergency stocks dangerously thin. One more significant flare up and we could be in trouble. Given the speed with which Yellow Fever can spread and given its high mortality rate, which is even higher among those from non-endemic areas, the consequences could be horrific.</p><p>Stepping up mosquito control is clearly one priority, but the increasing spread of Dengue, Zika and Chikungunya which are transmitted by the same species show how this is not working. So we also desperately need to increase vaccine production too. The trouble is we already have and it’s not enough. In Gavi/<a href="https://medium.com/u/9cfe9541ba9c">UNICEF</a>-supported countries, demand surged from around 5 million doses a year in 2000 to 55 million today. Manufacturers have tried to keep pace, but the egg-based production of Yellow Fever vaccine is relatively slow and difficult to scale-up. As a result, today’s demand still outstrips existing supplies by around 10%.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*X8Oy-f2sSMz9Em-EmYM8EQ.jpeg" /><figcaption>The Yellow Fever vaccine. Photo credit: <a href="http://www.paho.org/hq/">PAHO</a></figcaption></figure><p>Beyond shortfalls in production against current estimates of demand, another important driver for the inability to respond most effectively to today’s outbreak in Angola is that our risk assessment is out-of-date. Because of climate change, human and animal migration and increasing urbanization, the behavior and spread of Yellow Fever has shifted over time and may be threatening many more areas. This makes it probable that current estimates for required supply underestimate true need. The challenge now is finding ways to make up this shortfall and get ahead on production.</p><p>In such situations, the global health community normally has an effective tool to help boost global production. It can hike up prices to either stimulate investment from existing suppliers, or to try to encourage new manufacturers to enter the market. However, Yellow Fever appears to defy conventions. We already have four suppliers, making it a relatively competitive market and prices have already increased by close to 100% over the last decade-and-a-half.</p><p>Acting as a counter force, there is the rising cost of manufacturing vaccines. Compared to when the Yellow Fever vaccine was first developed at the Rockefeller Institute in the 1930s, modern manufacturing practices are more stringent, requiring a much higher level of production, quality and safety control. This is as it should be, but it comes at a cost. So the big question is what incentives do we need to put in place to encourage manufacturers to make the significant investments necessary to boost vaccine production?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*yuj_lBB5uzMcyk51_-x87Q.jpeg" /><figcaption>Yellow Fever vaccination in Angola. Photo credit: <a href="http://www.who.int/en/">WHO</a>/K. Nishino</figcaption></figure><p>While some critics argue that the price of new, state-of-the-art vaccines should be brought down to match older ones, which cost just tens of cents per dose, Yellow Fever is the chilling example that suggests the trend may need to sometimes go the other way. For older vaccines that have fairly predictable demand forecasts and established supply capacity is adequate to meet demand, it may well be feasible to continue selling them for the same price as three decades ago. But when it comes to investing for wider-scale use, where it can cost hundreds of millions of dollars to set up a new production facility, those economic-models go out the window.</p><blockquote>The point is that we desperately need a reboot.</blockquote><p>Our risk assessment of Yellow Fever has to be brought up-to-date and our strategies adapted accordingly. This could mean entering into discussions with manufacturers to determine what further incentives are necessary to meet demand, and that could result in anything from different price structures to multi-year demand forecasts or subsidies for new production lines. Such solutions may not sit well with everyone, but in the current market place the rules of economics clearly aren’t giving us what we need. We also need to be sure that coverage of Yellow Fever is high in countries that have it in their routine immunization programs. So, given that there is no cure or treatment for Yellow Fever, if we want to avoid a return of the kind of urban epidemics that afflicted cities two centuries ago and prevent Yellow Fever from re-establishing itself, then we need to be prepared to do what it takes to achieve vaccine security.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=db80bf19dae5" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[From medical drones to mobile apps — the power of making live-saving technology work for all]]></title>
            <link>https://medium.com/@GaviSeth/from-medical-drones-to-mobile-apps-the-power-of-making-live-saving-technology-work-for-all-5124748629e9?source=rss-4f701633ecd------2</link>
            <guid isPermaLink="false">https://medium.com/p/5124748629e9</guid>
            <category><![CDATA[vaccines]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[technology]]></category>
            <dc:creator><![CDATA[Seth Berkley]]></dc:creator>
            <pubDate>Tue, 31 May 2016 09:08:55 GMT</pubDate>
            <atom:updated>2016-05-31T09:08:55.049Z</atom:updated>
            <content:encoded><![CDATA[<p>As CEO of Gavi, the Vaccine Alliance, my day-to-day work involves helping the poorest countries access immunisation — a technology that people in wealthier countries sometimes take for granted. But after 15 years of work we know that it is neither sustainable, nor advisable for this technology to stand alone.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4fjlGDakMVmWXGXmHW25sA.jpeg" /><figcaption>A nurse prepares to vaccinate a baby at a health clinic in Sierra Leone, 2016. Photo: Gavi / Kate Holt</figcaption></figure><p>Behind a single shot given to a child, there are health workers, clinics, vehicles, refrigerators and much more. Without all these, true vaccination progress cannot be achieved, and protection cannot reach the most marginalised communities. To ensure vaccines reach as many children as possible, a supporting system of innovative technology and infrastructure is required.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*oyH3DHf1KMcisGRMxeMyUw.jpeg" /><figcaption>Health workers delivering vaccines to a remote area in Nigeria, 2013. Photo: Gavi / Adrian Brooks</figcaption></figure><p>Delivery is an obvious area for this. Only last week I saw a <a href="http://www.vaccineswork.org/post/144246552657/getting-life-saving-medicines-from-the-sky">test drone flight</a> streamed from a camera, which will soon be used as part of a national delivery system to transport vital vaccines and medical supplies to remote regions in Rwanda, where it can currently take hours to drive even small distances.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*jexdj5yKNlGjZYjwf-E-Ng.jpeg" /><figcaption>A medical drone on a test flight, 2016. Photo: UPS</figcaption></figure><p>Cooling technology is also coming on leaps and bounds. As domestic <a href="http://www.theverge.com/circuitbreaker/2016/5/4/11591780/samsung-family-hub-smart-fridge-hands-on-price-release-date">smart fridges</a> are developed in some parts of the world, Gavi is <a href="http://www.gavi.org/support/hss/cold-chain-equipment-optimisation-platform/">working with the poorest countries</a> to encourage the development of new ultra-efficient refrigeration technology that can keep vaccines safe for long periods even when there is no power. Solar power technology is also being used to allow vaccine vials (and other medicines) to be stored, transported and delivered at a safe temperature.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XWmkjAjdvMGdNvPvmUSCng.jpeg" /><figcaption>A nurse prepares syringes for vaccines kept in a solar fridge in DRC, 2015. Photo: Gavi / Phil Moore</figcaption></figure><p>And let’s not forget online, cloud-based systems that are opening up to greater numbers of businesses and individuals than ever before. To build on this, we’re working with countries and other Alliance partners on the early stages of a <a href="http://www.gavi.org/Support/Apply/Country-portal/">web portal</a> where all country information can be stored and through which applications for vaccine support can be made. This can reduce the risk of error and duplication, helping countries get the vaccines and information they need, while enabling stakeholders to track process.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*8wcAaK2nSaFEsx6s8OO4yA.jpeg" /><figcaption>A smartphone app used by vaccinators in Pakistan, 2016. Photo: Gavi / Isaac Griberg</figcaption></figure><p>Smart phones are another area revolutionising health and immunisation. In Punjab, Pakistan, a smartphone app <a href="http://dunyanews.tv/en/Technology/311628-Punjab-eVaccs-Program-brings-remarkable-improveme">to track vaccinators travelling to remote areas</a> has boosted vaccine coverage significantly over a single year. Another system in India <a href="http://www.in.undp.org/content/india/en/home/ourwork/health/successstories/people-processes-and-products.html">tracks vaccine stock from national to local levels</a>, making sure that there are enough vaccines for everyone attending clinics.</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fwww.youtube.com%2Fembed%2FAq0Km2OF-rs%3Ffeature%3Doembed&amp;url=http%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DAq0Km2OF-rs&amp;image=https%3A%2F%2Fi.ytimg.com%2Fvi%2FAq0Km2OF-rs%2Fhqdefault.jpg&amp;key=d04bfffea46d4aeda930ec88cc64b87c&amp;type=text%2Fhtml&amp;schema=youtube" width="854" height="480" frameborder="0" scrolling="no"><a href="https://medium.com/media/a4db66540a54585f8cde0ffe372ed7fd/href">https://medium.com/media/a4db66540a54585f8cde0ffe372ed7fd/href</a></iframe><p>Gavi’s aim is to help vaccine technology reach every last child, a mission made all the more challenging if we do not seek to redress other technological inequities. We therefore have a responsibility to innovate, to help countries make the most of available technologies, and even <a href="https://www.technologyreview.com/s/601425/in-global-shift-poorer-countries-are-increasingly-the-early-tech-adopters/">become early adopters</a> where possible.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*evOeGkf3V6VA4JAEJUvsJA.jpeg" /><figcaption>Mwanahawsi has his general health recorded by a data clerk in Kenya, 2013. Photo: Gavi / Evelyn Hockstein</figcaption></figure><p>So while vaccines have a clear role in saving lives, they are just one of the technologies that make this possible. By recognising this we can not only do a better job of preventing disease, but also help to catalyse health systems and wider technological change that can bring <a href="https://medium.com/@GaviSeth/dignity-through-access-to-technology-fac125b4f605#.c5itpjbfs">health and dignity</a> to communities around the world.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5124748629e9" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Survival, sanitation and syringes: three decades of preventing disease in Uganda]]></title>
            <link>https://medium.com/@GaviSeth/survival-sanitation-and-syringes-three-decades-of-preventing-disease-in-uganda-eb4da6ba706f?source=rss-4f701633ecd------2</link>
            <guid isPermaLink="false">https://medium.com/p/eb4da6ba706f</guid>
            <category><![CDATA[uganda]]></category>
            <category><![CDATA[vaccines]]></category>
            <category><![CDATA[public-health]]></category>
            <dc:creator><![CDATA[Seth Berkley]]></dc:creator>
            <pubDate>Wed, 04 May 2016 15:06:13 GMT</pubDate>
            <atom:updated>2016-05-04T16:15:54.427Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/500/1*e_8jien1tmHkOzZFBCOW2Q.jpeg" /><figcaption><em>An expectant crowd wait for the launch of pneumococcal vaccine in Iganga, in 2013. Photo: Gavi/ Michele Sibiloni.</em></figcaption></figure><p>I first worked in Uganda in 1987. I moved there from Massachusetts where I was working on infectious disease epidemiology on assignment from the Centers for Disease Control in the US. Uganda is where I learned about the difficulties of inadequate health and information systems, and how unequal the experiences of children in Africa were with their counterparts in the developed world.</p><p>For a snapshot, back then 191 Ugandan children <a href="http://databank.worldbank.org/data/reports.aspx?source=2&amp;country=uga&amp;series=&amp;period=">out of every 1,000</a> died before reaching the age of five, and the full course of basic diphtheria, tetanus and pertussis (DTP) shots only reached 21% of kids. I had gone there on assignment from the Task Force for Child Survival at the Carter Center to help rebuild the immunization and surveillance systems after many years of chaos, and I recall that these sort of statistics were not uncommon for many African countries at the time.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*dfuJ2B3F70TZAxb8_JnsWA.jpeg" /><figcaption>With a Ministry of Health colleague in Uganda in the late 80s.</figcaption></figure><p>Even the processes around vaccination needed to be brought up to scratch to make it as safe for children in Uganda as it was in, say, the United States. One of the critical checks when visiting a clinic back then was to see whether they had any sterilisation equipment for the reusable syringes and needles (they mostly didn’t) and how they disposed of the disposable syringes. HIV/AIDS was just emerging, and the risks associated with reuse were higher than ever, but resources were overstretched. Since they often didn’t have incinerators in those days, health workers were supposed to dispose of contaminated equipment by throwing it down the latrine. I found this to be useful, since we could check whether clinics were really destroying syringes. I once went with Jimmy Carter to visit a set of clinics, and I remember the horror of the health team as we actually checked. We took a flashlight and looked down the toilet to see if there were syringes down there. Of course, there never were.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/500/1*FMmbX9Kq6gRQ6XHLJDCtQQ.jpeg" /><figcaption><em>The immunization report I authored in 1987. Photo: Gavi / Isaac Griberg.</em></figcaption></figure><p>Almost thirty years later, the picture has changed enormously. Some of the essential work took place even before we could even get new vaccines out to the world’s poorest countries — first, countries needed a safe platform for immunization. Auto-disable syringes and proper disposal facilities soon enabled vaccination to be as technically safe in developing countries as elsewhere (one of the <a href="http://www.gavi.org/library/news/roi/2010/gavi-catalyses-new-injection-safety-standards/">first things Gavi did</a> in the early 2000s), paving the way for more vaccine protection being delivered to more children than ever before. Many other things have changed too. In 1987, we had 15 road blocks on the Entebbe-Kampala road. Today the biggest risk is traffic on the nice highway between the two.</p><p>Looking at the statistics, Uganda’s progress is clear. Child mortality is now <a href="http://databank.worldbank.org/data/reports.aspx?source=2&amp;country=uga&amp;series=&amp;period=">55 per 1,000</a>, with the basic package of vaccines reaching around <a href="http://www.gavi.org/country/uganda/">78% of kids</a> — not perfect, but a huge improvement. More than that, Ugandan children now have greater access to vaccines that protect against a whole range of diseases, from hepatitis B to pneumonia. Recently they added two more — <a href="http://www.afro.who.int/en/uganda/press-materials/item/8186-uganda-launches-human-papillomavirus-vaccine.html">HPV vaccines</a> are now protecting girls from cervical cancer later in life, and <a href="http://www.afro.who.int/en/uganda/press-materials/item/8560-uganda-introduces-the-inactivated-polio-vaccine-ipv-into-its-routine-immunization-program.html">inactivated polio vaccine </a>is being used across the country.</p><p>A few things have remained the same though. When Uganda launched pneumococcal vaccine in 2013, it was President Museveni who attended the launch, just as he had attended child health meetings all those years ago.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/500/1*xB_JG0ff3OcUJ-azoUGfyA.jpeg" /><figcaption>Celebrating the launch of pneumococcal vaccine in 2013 with President Museveni. Photo: Gavi/ Michele Sibiloni.</figcaption></figure><p>The predominant trend is positive change in Uganda and across Africa, with better infrastructure and more lives being saved thanks to safe and still-expanding immunization programs. When I contemplate my work back then and the role I now have supporting global vaccination at Gavi, I’m proud to have been part of it.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=eb4da6ba706f" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Immunisation — the gateway to health and prosperity]]></title>
            <link>https://medium.com/@GaviSeth/immunisation-the-gateway-to-health-and-prosperity-706a0b7db120?source=rss-4f701633ecd------2</link>
            <guid isPermaLink="false">https://medium.com/p/706a0b7db120</guid>
            <category><![CDATA[vaccines]]></category>
            <category><![CDATA[economics]]></category>
            <category><![CDATA[global-health]]></category>
            <dc:creator><![CDATA[Seth Berkley]]></dc:creator>
            <pubDate>Thu, 28 Apr 2016 16:29:22 GMT</pubDate>
            <atom:updated>2016-04-28T16:29:22.818Z</atom:updated>
            <content:encoded><![CDATA[<p>We know vaccines work to prevent disease and save lives. This much has been clear since the very early days, but understanding and quantifying the scale of vaccines’ true value is a more recent contribution. Just recently, in February, <a href="http://content.healthaffairs.org/content/35/2/199.abstract">research revealed</a> that every dollar invested in childhood immunisation can provide a short term return of US$16, when considering the cost of treating illness. However, in the longer term, using the full income approach where one values the years of additional life gained, the effects of vaccination can be even bigger, providing a US$44 return in light of better school performance, improved quality of life and increased productivity. This means we can confidently outline how vaccination boosts prosperity, making the case for immunisation around the world, helping governments understand the need to invest in prevention, not just in terms of lives saved but in economic terms too.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Gkm2CubhewNrWorUqlPPRw.jpeg" /></figure><p>But the potential of vaccination does not end here. As I often remind people, with more than 30 doses administered worldwide every second, no other health intervention reaches so many children. The point of this, aside from recognising the sheer scale of its achievements, is to highlight how vaccination can be used to build health systems in resource poor settings. For many people in developing countries, vaccination is an established but reasonably rare point of contact with the health system. As Ebola and its fallout continues to demonstrate, health systems that can deal with a variety of diseases at any given time and are trusted by communities are invaluable. With this in mind, governments of the poorest countries and global health leaders are already exploring how immunisation can function as a backbone to other services, whether that be contraception in Pakistan or nutrition supplements in Bangladesh.<br> <br>So it’s time we started thinking even beyond the (impressive) immediate benefits of vaccination, and made the most of its capacity to contribute meaningfully to building universal healthcare systems and prosperous societies across the world.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=706a0b7db120" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>